These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20977485)

  • 1. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function.
    Galan AM; Lozano M; Molina P; Navalon F; Marschner S; Goodrich R; Escolar G
    Transfusion; 2011 Apr; 51(4):808-15. PubMed ID: 20977485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated preparation of whole blood-derived platelets suspended in two different platelet additive solutions and stored for 7 days.
    Cid J; Magnano L; Molina P; Diaz-Ricart M; Martínez N; Maymó RM; Puig L; Lozano M; Escolar G; Galán AM
    Transfusion; 2014 Feb; 54(2):426-33. PubMed ID: 23721299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
    Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
    Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
    Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
    Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality.
    Ringwald J; Walz S; Zimmermann R; Zingsem J; Strasser E; Weisbach V; Eckstein R
    Vox Sang; 2005 Jul; 89(1):11-8. PubMed ID: 15938735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR; Thurman G; Marschner S; Goodrich RP
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution.
    Cookson P; Sutherland J; Turner C; Bashir S; Wiltshire M; Hancock V; Smith K; Cardigan R
    Transfus Med; 2010 Dec; 20(6):392-402. PubMed ID: 20738829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction.
    Isola H; Ravanat C; Rudwill F; Pongerard A; Haas D; Eckly A; Gachet C; Hechler B
    Transfusion; 2021 Mar; 61(3):919-930. PubMed ID: 33527430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.
    Johnson L; Winter KM; Hartkopf-Theis T; Reid S; Kwok M; Marks DC
    Transfusion; 2012 Mar; 52(3):503-9. PubMed ID: 21880041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
    Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
    Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion.
    Rijkers M; van der Meer PF; Bontekoe IJ; Daal BB; de Korte D; Leebeek FW; Voorberg J; Jansen AJ
    Vox Sang; 2016 Oct; 111(3):247-256. PubMed ID: 27184018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
    Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
    Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
    Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
    Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
    Picker SM; Steisel A; Gathof BS
    Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
    Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
    Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.